Applied Biological Materials (abm)

SLC35A1 CRISPR Stable Knockout CHO-S Cell Line

Product Code:
 
ABM-T6040
Product Group:
 
Cell Lines
Host Type:
 
Hamster
Regulatory Status:
 
RUO
 

No additional charges, what you see is what you pay! *

CodeSizePrice
ABM-T60401x10^6 cells / 1 mlEnquire
An MTA must be signed before products can be dispatched. Please contact us for more information.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges to UK mainland customers, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Canada.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Related Products
  • Show All

Further Information

Description:
SLC35A1 encodes a CMP-sialic acid transporter located within the membrane of the Golgi apparatus. CHO-S cells isolated from Chinese Hamster ovary were transfected with CRISPR/Cas9 plasmids which target SLC35A1 to generate the SLC35A1 CRISPR Knock Out CHO-S Cell Line (Hamster). This sialic acid-deficient cell line is useful for research focusing on SLC35A1 as it functions in transporting nucleotide sugars into the Golgi where glycosyltransferases function. The SLC35A1 CRISPR Knock Out CHO-S Cell Line (Hamster) is also useful in characterization of anti-glycopeptide monoclonal antibodies.
Donor History:
Female, Adult, Chinese hamster
Growth Conditions:
PriGrow X Series Medium (TM6040) + 1% Penicillin/Streptomycin Solution (G255), 37.0°C, 5% CO2
Growth Properties:
Suspension, round
Population Doubling:
16 - 22
Seeding Density (/ml):
200,000
Tissue:
Ovary

References

Kaneko, M. K., Nakamura, T., Honma, R., Ogasawara, S., Fujii, Y., Abe, S., . . . Kato, Y. (2017). Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Medicine, 6(2), 382-396. doi:10.1002/cam4.954